Maine LD627 mandates insurance coverage for glucagon-like peptide-1 receptor agonist medication and limits out-of-pocket costs.
Maine LD627 requires health insurance carriers in the state to cover glucagon-like peptide-1 receptor agonist medication approved by the FDA and prescribed by a healthcare provider. The bill also limits out-of-pocket costs for enrollees to no more than $35 per prescription for a 30-day supply. It prohibits carriers from imposing any prior authorization requirements for coverage.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
Analyze for Free
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.